xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.
Company profile
Ticker
XENE
Exchange
Website
CEO
Simon Pimstone
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
XENE stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
19 Apr 24
8-K
Other Events
8 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24
424B5
Prospectus supplement for primary offering
30 Nov 23
8-K
Entry into a Material Definitive Agreement
30 Nov 23
424B5
Prospectus supplement for primary offering
29 Nov 23
8-K
Other Events
27 Nov 23
8-K
Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences
9 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
Transcripts
XENE
Earnings call transcript
2023 Q4
29 Feb 24
XENE
Earnings call transcript
2023 Q3
8 Nov 23
XENE
Earnings call transcript
2023 Q2
9 Aug 23
XENE
Earnings call transcript
2023 Q1
9 May 23
XENE
Earnings call transcript
2022 Q4
1 Mar 23
XENE
Earnings call transcript
2022 Q3
9 Nov 22
XENE
Earnings call transcript
2022 Q2
10 Aug 22
XENE
Earnings call transcript
2022 Q1
10 May 22
XENE
Earnings call transcript
2021 Q4
2 Mar 22
XENE
Earnings call transcript
2021 Q3
11 Nov 21
Latest ownership filings
4
Seggern Christopher Von
12 Mar 24
4
SHERRY AULIN
12 Mar 24
4
CHRISTOPHER JOHN KENNEY
12 Mar 24
4
JAMES R. EMPFIELD
12 Mar 24
4
SHERRINGTON ROBIN
12 Mar 24
4
Andrea DiFabio
12 Mar 24
4
IAN MORTIMER
12 Mar 24
4
ELIZABETH A. GAROFALO
11 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
SHERRINGTON ROBIN
8 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 99.57 mm | 99.57 mm | 99.57 mm | 99.57 mm | 99.57 mm | 99.57 mm |
Cash burn (monthly) | (no burn) | 326.25 k | 18.56 mm | 16.97 mm | 14.08 mm | 11.88 mm |
Cash used (since last report) | n/a | 2.18 mm | 124.17 mm | 113.55 mm | 94.17 mm | 79.49 mm |
Cash remaining | n/a | 97.39 mm | -24.59 mm | -13.98 mm | 5.41 mm | 20.08 mm |
Runway (months of cash) | n/a | 298.5 | -1.3 | -0.8 | 0.4 | 1.7 |
Institutional ownership, Q3 2023
82.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 181 |
Opened positions | 24 |
Closed positions | 16 |
Increased positions | 70 |
Reduced positions | 48 |
13F shares | Current |
---|---|
Total value | 2.06 tn |
Total shares | 62.55 mm |
Total puts | 434.01 k |
Total calls | 159.20 k |
Total put/call ratio | 2.7 |
Largest owners | Shares | Value |
---|---|---|
Avoro Capital Advisors | 4.90 mm | $167.38 bn |
Driehaus Capital Management | 4.51 mm | $154.16 bn |
FMR | 4.25 mm | $145.28 bn |
Polar Capital | 3.00 mm | $102.61 bn |
Capital International Investors | 2.45 mm | $83.58 bn |
Capital World Investors | 2.27 mm | $77.71 bn |
Marshall Wace | 2.15 mm | $73.59 bn |
Braidwell | 2.10 mm | $71.85 bn |
Pictet Asset Management Holding | 1.94 mm | $66.23 bn |
Commodore Capital | 1.85 mm | $63.03 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Mar 24 | Andrea DiFabio | Stock Option Common Shares | Grant | Acquire A | No | No | 44.37 | 100,000 | 4.44 mm | 100,000 |
11 Mar 24 | Mortimer Ian | Stock Option Common Shares | Grant | Acquire A | No | No | 44.37 | 250,000 | 11.09 mm | 250,000 |
11 Mar 24 | Robin Sherrington | Stock Option Common Shares | Grant | Acquire A | No | No | 44.37 | 65,000 | 2.88 mm | 65,000 |
11 Mar 24 | Christopher John Kenney | Stock Option Common Shares | Grant | Acquire A | No | No | 44.37 | 100,000 | 4.44 mm | 100,000 |
11 Mar 24 | Empfield James R. | Stock Option Common Shares | Grant | Acquire A | No | No | 44.37 | 65,000 | 2.88 mm | 65,000 |
News
Xenon Pharmaceuticals Announced Two Oral Presentations For XEN1101 Clinical Data At AAN 2024 Annual Meeting
16 Apr 24
Needham Reiterates Buy on Xenon Pharmaceuticals, Maintains $62 Price Target
12 Apr 24
Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target
10 Apr 24
RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Lowers Price Target to $55
1 Mar 24
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $51
1 Mar 24
Press releases
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
10 Apr 24
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
4 Apr 24
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
12 Mar 24
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
5 Mar 24
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 Feb 24